IVVD — Invivyd, Inc.

Summary of Invivyd, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenues: Invivyd reported Q4 2025 net revenues of $53.4 million, reflecting a 31% increase from Q3 2025 and a 25% increase year-over-year from Q4 2024.
• Cash Position: The company ended the year with $226.7 million in cash and cash equivalents, following a capital raise of over $200 million in 2025, positioning it well for upcoming pivotal data for VYD2311 expected in mid-2026.

2. Strategic Updates and Business Highlights

• Clinical Programs: The Revolution clinical program is progressing, with the Declaration study for VYD2311 reaching target enrollment of approximately 1,770 subjects. The study aims to evaluate the safety and efficacy of VYD2311 as a prophylactic treatment against symptomatic COVID-19.
• Commercial Growth: Invivyd's PEMGARDA product continues to gain traction, with a growing number of healthcare providers (HCPs) utilizing the treatment, evidenced by a 77% reorder rate among accounts.
• Pipeline Expansion: The company is advancing its RSV antibody program, claiming it to be potentially best-in-class, and is exploring applications for long COVID and post-vaccine syndrome.
• Partnerships and Collaborations: Invivyd is collaborating with academic thought leaders to address long COVID and vaccine injury, and has secured over 15,000 contracted GPO sites, expanding its commercial footprint.

3. Forward Guidance and Outlook

• Clinical Data Timeline: The company anticipates providing updates on the Declaration study in Q2 or Q3 2026, with potential for trial resizing based on event rates. The resizing decision is expected around April 2026.
• Future Programs: Updates on the measles antibody program are expected in the first half of 2026, with potential use cases including outbreak prophylaxis and pediatric applications.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The company faces inherent risks associated with clinical trials, including the potential for lower-than-expected vaccine efficacy and the need for trial resizing, which could delay timelines.
• Market Competition: Invivyd's entry into the RSV market will face established competition from existing products, which may challenge market penetration.
• COVID-19 Variability: The ongoing evolution of COVID-19 and its variants poses uncertainty regarding the effectiveness of monoclonal antibody treatments and the overall market demand.

5. Notable Q&A Insights

• Trial Resizing Criteria: Management clarified that resizing of the Declaration trial would depend on the expected vaccine efficacy and the number of COVID events. The decision aims to ensure adequate statistical power for the study.
• Secondary Endpoints: While the primary focus is on symptomatic COVID-19 prevention, the company will collect secondary data on viral load and healthcare utilization, although these may not significantly impact study power.
• Measles Antibody Use Cases: The potential use cases for the measles antibody include outbreak prophylaxis and bridging therapy for pediatric patients, with a focus on enhancing vaccination outcomes.

Overall, Invivyd, Inc. demonstrated strong financial growth and strategic positioning in the monoclonal antibody space while navigating challenges related to clinical trials and market competition.